KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) EBITDA (2016 - 2025)

Historic EBITDA for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $217.9 million.

  • Halozyme Therapeutics' EBITDA rose 3353.25% to $217.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $737.4 million, marking a year-over-year increase of 5458.79%. This contributed to the annual value of $551.5 million for FY2024, which is 6336.42% up from last year.
  • Halozyme Therapeutics' EBITDA amounted to $217.9 million in Q3 2025, which was up 3353.25% from $202.4 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' EBITDA registered a high of $217.9 million during Q3 2025, and its lowest value of $34.1 million during Q2 2022.
  • In the last 5 years, Halozyme Therapeutics' EBITDA had a median value of $93.0 million in 2021 and averaged $105.0 million.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 167415.45% in 2021, then tumbled by 6339.48% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' EBITDA (Quarter) stood at $56.5 million in 2021, then skyrocketed by 31.8% to $74.5 million in 2022, then skyrocketed by 35.6% to $101.0 million in 2023, then soared by 73.7% to $175.5 million in 2024, then increased by 24.17% to $217.9 million in 2025.
  • Its EBITDA stands at $217.9 million for Q3 2025, versus $202.4 million for Q2 2025 and $141.5 million for Q1 2025.